Complement inhibition alleviates paraquat-induced acute lung injury

American Journal of Respiratory Cell and Molecular Biology

Volumn 45, Issue 4, 2011, Pages 834-842

  Sun, Shihui ^a   Wang, Hanbin ^b   Zhao, Guangyu ^a   An, Yingbo ^b   Guo, Yan ^a   Du, Lanying ^c   Song, Hongbin ^a   Qiao, Fei ^d   Yu, Hong ^a   Wu, Xiaohong ^a   Atkinson, Carl ^d   Jiang, Shibo ^c   Tomlinson, Stephen ^d   Zhou, Yusen ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b Beijing 307 Hospital   (China)

^c NEW YORK BLOOD CENTER   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Acute lung injury; Complement; Inhibitor; Mouse model; Paraquat

Indexed keywords

COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3 INHIBITOR; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3A RECEPTOR; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT INHIBITOR; COMPLEMENT RECEPTOR; COMPLEMENT RECEPTOR 2 COMPLEMENT FACTOR H; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY COMPLEMENT COMPONENT C5A RECEPTOR; PARAQUAT; RECEPTOR BLOCKING AGENT; SB 290157; UNCLASSIFIED DRUG;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; LUNG INJURY; MORTALITY; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; SURVIVAL; WILD TYPE;

ACUTE LUNG INJURY; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COMPLEMENT ACTIVATION; COMPLEMENT C1Q; COMPLEMENT C3; DISEASE MODELS, ANIMAL; LUNG; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PARAQUAT; RECEPTOR, ANAPHYLATOXIN C5A; RECEPTORS, COMPLEMENT; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; TIME FACTORS;

MUS;

EID: 80053648481     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2010-0444OC     Document Type: Article

References (49)

1. Onyeama HP, Oehme FW. A literature review of paraquat toxicity. Vet Hum Toxicol 1984;26:494-502. (Pubitemid 15195529)
2. Chan BS, Lazzaro VA, Seale JP, Duggin GG. The renal excretory mechanisms and the role of organic cations in modulating the renal handling of paraquat. Pharmacol Ther 1998;79:193-203. (Pubitemid 28393875)
3. Dinis-Oliveira RJ, Remiao F, Carmo H, Duarte JA, Navarro AS, BastosML, Carvalho F. Paraquat exposure as an etiological factor of Parkinson?s disease. Neurotoxicology 2006;27:1110-1122. (Pubitemid 44838957)
4. Dinis-Oliveira RJ, De Jesus Valle MJ, Bastos ML, Carvalho F, Sanchez Navarro A. Kinetics of paraquat in the isolated rat lung: influence of sodium depletion. Xenobiotica 2006;36:724-737. (Pubitemid 44195986)
5. Sittipunt C. Paraquat poisoning. Respir Care 2005;50:383-385. (Pubitemid 46179557)
6. Suntres ZE. Role of antioxidants in paraquat toxicity. Toxicology 2002; 180:65-77. (Pubitemid 35248093)
7. Bus JS, Aust SD, Gibson JE. Paraquat toxicity: proposed mechanism of action involving lipid peroxidation. Environ Health Perspect 1976;16: 139-146. (Pubitemid 8037539)
8. Bonneh-Barkay D, Reaney SH, Langston WJ, Di Monte DA. Redox cycling of the herbicide paraquat in microglial cultures. Brain Res Mol Brain Res 2005;134:52-56. (Pubitemid 40403639)
9. Ward PA. The dark side of C5a in sepsis. Nat Rev Immunol 2004;4: 133-142. (Pubitemid 38209207)
10. Robbins RA, Russ WD, Rasmussen JK, Clayton MM. Activation of the complement system in the adult respiratory distress syndrome. Am Rev Respir Dis 1987;135:651-658. (Pubitemid 17041600)
11. Linton SM, Morgan BP. Complement activation and inhibition in experimental models of arthritis. Mol Immunol 1999;36:905-914. (Pubitemid 30100843)
12. Welch TR. Complement in glomerulonephritis. Nat Genet 2002;31:333-334. (Pubitemid 35154438)
13. Hawlisch H, Wills-Karp M, Karp CL, Kohl J. The anaphylatoxins bridge innate and adaptive immune responses in allergic asthma. Mol Immunol 2004;41:123-131. (Pubitemid 38668621)
14. Hawlisch H, Belkaid Y, Baelder R, Hildeman D, Gerard C, Kohl J. C5a negatively regulates toll-like receptor 4-induced immune responses. Immunity 2005;22:415-426. (Pubitemid 40545108)
15. Guo RF, Riedemann NC, Ward PA. Role of C5a-C5aR interaction in sepsis. Shock 2004;21:1-7.
16. Guo RF, Ward PA. Role of C5a in inflammatory responses. Annu Rev Immunol 2005;23:821-852. (Pubitemid 40563186)
17. Kildsgaard J, Hollmann TJ, Matthews KW, Bian K, Murad F, Wetsel RA. Cutting edge: targeted disruption of the C3a receptor gene demonstrates a novel protective anti-inflammatory role for C3a in endotoxinshock. J Immunol 2000;165:5406-5409.
18. Baelder R, Fuchs B, Bautsch W, Zwirner J, Kohl J, Hoymann HG, Glaab T, Erpenbeck V, Krug N, Braun A. Pharmacological targeting of anaphylatoxin receptors during the effector phase of allergic asthma suppresses airway hyperresponsiveness and airway inflammation. J Immunol 2005;174:783-789. (Pubitemid 40094273)
19. Dinis-Oliveira RJ, Remiao F, Duarte JA, Ferreira R, Navarro AS, Bastos ML, Carvalho F. P-glycoprotein induction: an antidotal pathway for paraquat-induced lung toxicity. Free Radic Biol Med 2006;41: 1213-1224. (Pubitemid 44466319)
20. De Steenwinkel JE, De Knegt GJ, Ten Kate MT, Van Belkum A, Verbrugh HA, Hernandez-Pando R, Van Soolingen D, Bakker- Woudenberg IA. Immunological parameters to define infection progression and therapy response in a well-defined tuberculosis model in mice. Int J Immunopathol Pharmacol 2009;22:723-734.
21. Atkinson C, Song H, Lu B, Qiao F, Burns TA, Holers VM, Tsokos GC, Tomlinson S. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest 2005;115:2444-2453. (Pubitemid 41266206)
22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(2delta delta C(t)) method. Methods 2001;25:402-408. (Pubitemid 34164012)
23. Goldblum SE, Wu KM, Jay M. Lung myeloperoxidase as a measure of pulmonary leukostasis in rabbits. J Appl Physiol 1985;59:1978-1985. (Pubitemid 16158267)
24. Padilla-Docal B, Dorta-Contreras AJ, Fundora-Hernandez H, Noris- Garcia E, Bu-Coifiu-Fanego R, Gonzalez-Hernandez M, Rodriguez- Rey A. C3c intrathecal synthesis evaluation in patients with multiple sclerosis. Arq Neuropsiquiatr 2007;65:800-802.
25. Markiewski MM, Mastellos D, Tudoran R, DeAngelis RA, Strey CW, Franchini S, Wetsel RA, Erdei A, Lambris JD. C3a and C3b activation products of the third component of complement (C3) are critical for normal liver recovery after toxic injury. J Immunol 2004;173:747-754. (Pubitemid 38924248)
26. Huang Y, Qiao F, Atkinson C, Holers VM, Tomlinson S. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol 2008;181:8068-8076.
27. Qiao F, Atkinson C, Song H, Pannu R, Singh I, Tomlinson S. Complement plays an important role in spinal cord injury and represents a therapeutic target for improving recovery following trauma. Am J Pathol 2006;169:1039-1047. (Pubitemid 44411965)
28. Sun L, Guo RF, Gao H, Sarma JV, Zetoune FS, Ward PA. Attenuation of IgG immune complex-induced acute lung injury by silencing C5aR in lung epithelial cells. FASEB J 2009;23:3808-3818.
29. Bolger MS, Ross DS, Jiang H, Frank MM, Ghio AJ, Schwartz DA, Wright JR. Complement levels and activity in the normal and LPSinjured lung. Am J Physiol Lung Cell Mol Physiol 2007;292:L748- L759.
30. Rittirsch D, Flierl MA, Day DE, Nadeau BA, McGuire SR, Hoesel LM, Ipaktchi K, Zetoune FS, Sarma JV, Leng L, et al. Acute lung injury induced by lipopolysaccharide is independent of complement activation. J Immunol 2008;180:7664-7672.
31. Fleming SD, Mastellos D, Karpel-Massler G, Shea-Donohue T, Lambris JD, Tsokos GC. C5a causes limited, polymorphonuclear cell-independent, mesenteric ischemia/reperfusion-induced injury. Clin Immunol 2003;108:263-273. (Pubitemid 37117373)
32. Lindgren S, Laurell AB, Eriksson S. Complement components and activation in primary biliary cirrhosis. Hepatology 1984;4:9-14. (Pubitemid 14185417)
33. - generation by human neutrophils. Mol Immunol 2004;41:185-190.
34. Oroszlan M, Daha MR, Cervenak L, Prohaszka Z, Fust G, Roos A. MBL and C1q compete for interaction with human endothelial cells. Mol Immunol 2007;44:1150-1158. (Pubitemid 44415977)
35. Ikeda K, Sannoh T, Kawasaki N, Kawasaki T, Yamashina I. Serum lectin with known structure activates complement through the classical pathway. J Biol Chem 1987;262:7451-7454.
36. Liu H, Jensen L, Hansen S, Petersen SV, Takahashi K, Ezekowitz AB, Hansen FD, Jensenius JC, Thiel S. Characterization and quantification of mouse mannan-binding lectins (MBL-A and MBL-C) and study of acute phase responses. Scand J Immunol 2001;53:489-497. (Pubitemid 32382273)
37. Markiewski MM, Lambris JD. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol 2007; 171:715-727. (Pubitemid 47440971)
38. Monsinjon T, Gasque P, Chan P, Ischenko A, Brady JJ, Fontaine MC. Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. FASEB J 2003; 17:1003-1014. (Pubitemid 36681518)
39. Guo RF, Riedemann NC, Bernacki KD, Sarma VJ, Laudes IJ, Reuben JS, Younkin EM, Neff TA, Paulauskis JD, Zetoune FS, et al. Neutrophil C5a receptor and the outcome in a rat model of sepsis. FASEB J 2003;17:1889-1891.
40. Allen-Gipson DS, Floreani AA, Heires AJ, Sanderson SD, MacDonald RG, Wyatt TA. Cigarette smoke extract increases C5a receptor expression in human bronchial epithelial cells. J Pharmacol Exp Ther 2005;314:476-482. (Pubitemid 41058286)
41. Abe M. Complement activation and inflammation. Rinsho Byori 2006; 54:744-756.
42. Proctor LM, Strachan AJ, Woodruff TM, Mahadevan IB, Williams HM, Shiels IA, Taylor SM. Complement inhibitors selectively attenuate injury following administration of cobra venom factor to rats. Int Immunopharmacol 2006;6:1224-1232. (Pubitemid 43868182)
43. Agarwal R, Srinivas R, Aggarwal AN, Gupta D. Immunosuppresive therapy in lung injury due to paraquat poisoning: a meta-analysis. Singapore Med J 2007;48:1000-1005. (Pubitemid 351235252)
44. Dinis-Oliveira RJ, Pontes H, Bastos ML, RemiCrossed D signo F, Duarte JA, Carvalho F. An effective antidote for paraquat poisonings: the treatment with lysine acetylsalicylate. Toxicology 2009;255:187-193.
45. Saibara T, Toda K, Wakatsuki A, Ogawa Y, Ono M, Onishi S. Protective effect of 3-methyl-1-phenyl-2-pyrazolin-5-one, a free radical scavenger, on acute toxicity of paraquat in mice. Toxicol Lett 2003;143:51-54. (Pubitemid 36412172)
46. Cho JH, Yang DK, Kim L, Ryu JS, Lee HL, Lim CM, Koh YS. Inhaled nitric oxide improves the survival of the paraquat-injured rats. Vascul Pharmacol 2005;42:171-178. (Pubitemid 40463655)
47. Dinis-Oliveira RJ, Duarte JA, RemiCrossed D signo F, SÃnchez- Navarro A, Bastos ML, Carvalho F. Single high dose dexamethasone treatment decreases the pathological score and increases the survival rate of paraquat-intoxicated rats. Toxicology 2006;227:73-85. (Pubitemid 44402856)
48. Ahmed AA. Protective effect of montelukast on paraquat-induced lung toxicity in rats. Biosci Trends 2009;3:63-72.
49. Williams JH Jr, Fairshter RD, Ulich TR, Crosby S, Chen M, Rosario L, Vaziri ND. Adverse effects of (15S)-15-methyl-prostaglandin E1 in normal and paraquat-exposed rats. Toxicol Appl Pharmacol 1988;92:330-334. (Pubitemid 18079222)